Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma

Published: June 11, 2009
Abstract Views: 243
PDF: 335
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Belinostat (PXD101) is a hydroxamate pan HDAC inhibitor which demonstrates broad antineoplastic activity in vitro and in vivo. Phase I studies have shown that belinostat is well-tolerated and has had activity in T-cell malignancies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Foss, F., Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., & Lerner, A. (2009). Activity of Belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.527